UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.urogen.com
Company Research
Source: Seeking Alpha
Vincent Perrone - Senior Director of Investor Relations Elizabeth Barrett - President, CEO & Director Mark Schoenberg - Chief Medical Officer David Lin - Chief Commercial Officer Christopher Degnan - Chief Financial Officer Conference Call Participants Kelsey Goodwin - Piper Sandler & Co., Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Aydin Huseynov - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to UroGen Pharma's Fourth Quarter 2025 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. I'd now like to hand the conference over to Vincent Perrone, Senior Director of Investor Relations. Please go ahead. Vincent Perrone
Show less
Read more
Impact Snapshot
Event Time:
URGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
URGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
URGN
News
- Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Urogen Pharma (URGN) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..MarketBeat
- Urogen Pharma Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- UroGen (URGN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Urogen Pharma (URGN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $33.00 price target on the stock.MarketBeat
URGN
Earnings
- 3/2/26 - Beat
URGN
Analyst Actions
- 3/2/26 - Oppenheimer Holdings, Inc.
URGN
Sec Filings
- 3/2/26 - Form 10-K
- 3/2/26 - Form 8-K
- 3/2/26 - Form 8-K
- URGN's page on the SEC website